Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.
説明 | ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein. |
ターゲット&IC50 | Tyrosine phosphatase:, Tyrosine phosphatase:(ki)26.22 μM , ADAM17:31.6 μM |
In vitro | ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel.?ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model[1]. |
In vivo | In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth [1]. |
分子量 | 433.52 |
分子式 | C24H23N3O3S |
CAS No. | 667880-38-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (144.17 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZLDI-8 667880-38-8 Apoptosis Immunology/Inflammation Metabolism Neuroscience Proteases/Proteasome Stem Cells Phosphatase Immunology/Inflammation related Gamma-secretase pithelial-mesenchymal transition anti-tumor inhibit Sorafenib E-Cadherin N-Cadherin Notch Survivin Inhibitor NICD ADAM-17 ZLDI 8 cIAP1/2 Vimentin ZLDI8 inhibitor